Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:29:57 ON 25 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:30:07 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAR 2004 HIGHEST RN 667234-34-6
DICTIONARY FILE UPDATES: 24 MAR 2004 HIGHEST RN 667234-34-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10684644.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy

G2 N,NH,NH2

G3 OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,NH,NH2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 14:30:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 158438 TO ITERATE

100.0% PROCESSED 158438 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.06

L2 5 SEA SSS FUL L1

=> file cap[lus
'CAP0LUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 14:30:57 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Mar 2004 VOL 140 ISS 13
FILE LAST UPDATED: 24 Mar 2004 (20040324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 5 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:656421 CAPLUS
DN 139:197489
TI Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
IN Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
PA USA
SO U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 153,454.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003158232	A1	20030821	US 2002-294525	20021114
			US 2001-294380PP	20010530
			US 2002-153454 A2	20020522
US 2003092736	A1	20030515	US 2002-153454	20020522
			US 2001-294380PP	20010530

PATENT FAMILY INFORMATION:
FAN 2002:927185

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096358	A2	20021205	WO 2002-US16633	20020523
WO 2002096358	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-294380PP	20010530
EP 1390363	A2	20040225	EP 2002-729306	20020523

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

			US 2001-294380PP	20010530
			WO 2002-US16633W	20020523

OS MARPAT 139:197489
IT **477773-89-0P 477774-03-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(prepn of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 477773-89-0 CAPLUS
CN Benzenebutanamide, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 477774-03-1 CAPLUS
CN Benzenebutanamide, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; ≥1 of x2, x3 ≠ 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor-γ (PPARγ) and stimulators of peroxisome proliferator activated receptor-α (PPARα). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPARα and to PPARγ ligand binding domains with IC50 = 69 nM.

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:610450 CAPLUS
DN 139:164813
TI Preparation of imidazo[1,2-a]pyridine derivatives as antifungal agents
IN Takemura, Makoto; Takahashi, Hisashi; Kawakami, Katsuhiro; Takeshita, Hiroshi; Kimura, Youichi; Watanabe, Jun; Sugimoto, Yuichi; Kitamura, Akihiro; Nakajima, Ryohei; Kanai, Kazuo; Fujisawa, Tetsunori
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064422	A1	20030807	WO 2003-JP912	20030130

PI
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
JP 2002-22767 A 20020131

OS MARPAT 139:164813
IT **577776-39-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo[1,2-a]pyridine derivs. as antifungal agents with specific or selective 1,6-β-glucan)
RN 577776-39-7 CAPLUS
CN Benzenebutanoic acid, β-oxo-4-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



GI



I

AB The title compds. (I), salts thereof, or solvates of either [wherein the ring A = (un)substituted benzene ring or 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; R1 = H, halo, each (un)protected NH2, HO, or SH, NO2, cyano, CHO, CO2H, each (un)substituted CONH2, NH2, C1-10 alkyl, C1-10 alkylamino, C1-10 alkoxy, C1-10 alkylthio, C2-6 acyl, C2-7 alkoxycarbonyl, C3-10 cycloalkyl, C3-10 cycloalkylamino, C3-10 cycloalkyloxy, C3-10 cycloalkylthio, C4-10 cycloalkenyl, C4-10 cycloalkenylamino, C4-10 cycloalkenyloxy, C4-10 cycloalkenylthio, C6-10 aryl, C6-10 arylamino, or C6-10 aryloxy, etc.; R2 = H, halo, (un)protected NH2 or OH, NO2, cyano, CO2H, each (un)substituted CONH2, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C1-20 alkylamino, C1-20 alkoxy, C2-18 acyl, C2-18 alkoxycarbonyl, C3-10 cycloalkyl, C5-10 cycloalkenyl, C3-10 cycloalkylamino, or C4-16 cycloalkylalkyl, etc.; R3 = H, halo, (un)protected NH2, OH, or SH, NO2, cyano, CHO, CO2H, each (un)substituted CONH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkylthio, C2-5 acyl, or C2-5 alkoxycarbonyl, etc.; R4 = H, halo, (un)protected NH2 or OH, NO2, cyano, CO2H, SO3H, each (un)substituted CONH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-5 acyl, C2-5 alkoxycarbonyl, C1-6 alkylcarbonyloxy, or C1-6 alkyloxysulfonyl, etc.] are prepared These compds. have a wide spectrum of antifungal activity by a novel mechanism, i.e., specific or selective 1,6-β-glucan synthesis inhibition. Thus, 1-chloro-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile, (3S)-dimethylaminopyrrolidine, Et3N, and DMF were heated at 80° for 14 h in a sealed vessel to give 61% 1-[(3S)-dimethylpyrrolidin-1-yl]-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile formate (II). II showed min. inhibitory concentration of <0.063, <0.063, and 0.5 μg/mL against Saccharomyces cerevisiae, Candida glabrata, and C. krusei, resp. Pharmaceutical formulations, e.g. a capsule containing 1-[2-(diethylamino)ethylamino]-2-ethyl-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile, were described.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:964135 CAPLUS

DN 138:24543
TI Preparation of benzyloxyphenyloxobutyrates and related compounds for the treatment of metabolic disorders
IN Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.
PA Wellstat Therapeutics Corporation, USA
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100341	A2	20021219	WO 2002-US18388	20020612
US 2003149107	A1	20030807	US 2002-167839	20020612
			US 2001-297282PP	20010612

PI WO 2002100341 A2 20021219 WO 2002-US18388 20020612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-297282PP 20010612
US 2003149107 A1 20030807 US 2002-167839 20020612
US 2001-297282PP 20010612

OS MARPAT 138:24543
IT **478162-71-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzyloxyphenyloxobutyrates and related compds. for treatment of metabolic disorders)
RN 478162-71-9 CAPLUS
CN Benzenebutanoic acid, 4-[(2,6-difluorophenyl)methoxy]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)



GI



AB Biol. active title compds. [I; n = 1, 2; m, q, p = 0, 1; R5 = alkyl; R9 = H, halo, alkoxy; A = (halo-, alkyl-, perfluoromethyl-, alkoxy-,

perfluoromethoxy-substituted) Ph, (Me-, Et-substituted) cycloalkyl, 5-6 membered heteroarom. ring having 1-2 N, S, O atoms; X = CH2, Q = OR1, R1 = Et; or X = CH2CR12R13, CH2CH(NHAc), Q = OR1, R1 = H, alkyl; or X = CH2CH2, Q = NR10R11; R12, R13 = H, Me; 1 of R10, R11 = H, alkyl, OH, the other = H, alkyl], were prepared Thus, 4-(2-fluorobenzyloxy)acetophenone (preparation given) in THF and DMPU was treated with a solution of Li bis(trimethylsilyl)amide at -60°; after 10 min, tert-Bu bromoacetate was added followed by stirring for an addnl. 10 min and warming to room temperature for 4 h to give tert-Bu 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyrate. The latter was stirred with CF3CO2H in CH2Cl2 to give 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyric acid. Tested I showed antidiabetic activity in a variety of tests. I are useful in treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:927185 CAPLUS
DN 138:24716
TI Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
IN Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096358	A2	20021205	WO 2002-US16633	20020523
	WO 2002096358	A3	20030327		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-294380PP	20010530
	EP 1390363	A2	20040225	EP 2002-729306	20020523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-294380PP	20010530
				WO 2002-US16633W	20020523

PATENT FAMILY INFORMATION:
FAN 2003:656421

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003158232	A1	20030821	US 2002-294525	20021114
				US 2001-294380PP	20010530
				US 2002-153454 A2	20020522
	US 2003092736	A1	20030515	US 2002-153454	20020522
				US 2001-294380PP	20010530

OS MARPAT 138:24716

IT **477773-89-0P 477774-03-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 477773-89-0 CAPLUS
CN Benzenebutanamide, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 477774-03-1 CAPLUS
CN Benzenebutanamide, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-β-oxo-N-phenyl- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; ≥1 of x2, x3 ≠ 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, alkyl(halo)aryloxycarbonyl, alkoxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkyl, aminocarbonyl, substituted aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aryloxyarylalkyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylsulfinylarylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor-γ (PPARγ) and stimulators of peroxisome proliferator activated receptor-α (PPARα). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPARα and to PPARγ ligand binding domains with IC50 = 69 nM.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:22115 CAPLUS
DN 108:22115
TI Conformational effects on the oxidative coupling of benzyltetrahydroisoquinolines to morphinan and aporphine alkaloids
AU Burnett, Duane A.; Hart, David J.
CS Dep. Chem., Ohio State Univ., Columbus, OH, 43210, USA
SO Journal of Organic Chemistry (1987), 52(26), 5662-7
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 108:22115
IT **110698-50-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 110698-50-5 CAPLUS
CN Benzenepentanamide, 4-methoxy-N-[2-[3-methoxy-4-(phenylmethoxy)phenyl]ethyl]-γ-oxo-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH_2—Ph

GI



I



II

AB Conformationally rigid 1-benzyltetrahydroisoquinolines I (R = H, Me) were prepared Oxidation of I (R = H) with vanadium oxychloride or thallium(III) trifluoroacetate gave structure II related to aporphine alkaloids as did oxidation of I (R = Me) with vanadium oxyfluoride. Oxidation of I (R = H) with (diacetoxyiodo)benzene gave a mixture of structures related to aporphine and morphinan alkaloids.

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	37.26	192.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.47	-3.47

FILE 'MARPAT' ENTERED AT 14:32:23 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 12)(20040319/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6696581 24 FEB 2004
DE 10317487 19 FEB 2004

EP 1389746 18 FEB 2004
JP 2004059557 26 FEB 2004
WO 2004015164 19 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 14:32:30 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 13114 TO ITERATE

83.1% PROCESSED 10894 ITERATIONS (1 INCOMPLETE) 6 ANSWERS

100.0% PROCESSED 13114 ITERATIONS (1 INCOMPLETE) 6 ANSWERS
SEARCH TIME: 00.00.36

L4 6 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.42	302.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.47

FILE 'CAPLUS' ENTERED AT 14:33:16 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Mar 2004 VOL 140 ISS 13
FILE LAST UPDATED: 24 Mar 2004 (20040324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4
L5 6 L4

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:334658 CAPLUS
DN **138:368896**

TI Biologically active 4H-benzo[1,4]oxazin-3-ones useful as PPARγ agonists or antagonists

IN Burris, Thomas P.; Combs, Donald W.; Rybczynski, Philip J.; Dudash, Joseph

PA USA

SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. Ser. No. 854,302. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003083329	A1	20030501	US 2001-990461	20011121
				US 2000-203860PP	20000512
				US 2001-854302 A2	20010511
	US 2002165228	A1	20021107	US 2001-854302	20010511
	US 6555536	B2	20030429		
				US 2000-203860PP	20000512
	EP 1314729	A1	20030528	EP 2002-258024	20021121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				US 2001-990461 A	20011121

PATENT FAMILY INFORMATION:

FAN 2001:851139

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087862	A2	20011122	WO 2001-US15383	20010511
	WO 2001087862	A3	20020530		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-203860PP	20000512
				US 2001-854302 A	20010511
	US 2002165228	A1	20021107	US 2001-854302	20010511
	US 6555536	B2	20030429		
				US 2000-203860PP	20000512
	EP 1280784	A2	20030205	EP 2001-937335	20010511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-203860PP	20000512
				US 2001-854302 A	20010511
				WO 2001-US15383W	20010511

OS MARPAT 138:368896

GI



I



II

AB The invention is directed to 4H-benzo[1,4]oxazin-3-ones I and their stereoisomers, esters, salts, and prodrugs, useful as peroxisome proliferator activated receptor gamma (PPARγ) agonists or antagonists [wherein: A = (un)substituted aryl, heterocyclyl, or alkyl; Z1 = H, alkyl, aryl, heterocyclyl, OH or derivs., CO2H or derivs., NH2 or derivs., halo, etc.; Z2 = H, halo, alkyl; or Z1Z2 = atoms to form fused aromatic ring; n = 0-3; G = CO2R1, COCO2R1, CONR1R2, CF3, P(O)(OR1)(OR2), SH, tetrazolyl, certain heterocycles, etc.; E = H, alkyl, -CH2CH2OC6H4(CH2)nG; X = H2, O; R1, R2 = H, alkyl, aryl, heterocyclyl, aralkyl; or R1R2 = atoms to form 5- to 10-membered ring; with addnl. provisos]. Pharmaceutical compns. comprising the compds. and methods of treating conditions such as NIDDM and obesity are also disclosed. Over 130 specific compds. are listed, and 5 of the preferred compds. are claimed. For instance, the silyl-protected intermediate 2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2H-1,4-benzoxazin-3(4H)-one (preparation given) underwent a sequence of N-alkylation with Br(CH2)6F, desilylation, Mitsunobu reaction with Me (2-hydroxyphenyl)acetate, and alkaline saponification, to give the preferred compound
II. In an agonist intrinsic activity assay for induction of aP2 mRNA production, II gave a 64.9-fold increase over control.

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:964135 CAPLUS
DN **138:24543**
TI Preparation of benzyloxyphenyloxobutyrates and related compounds for the treatment of metabolic disorders
IN Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.
PA Wellstat Therapeutics Corporation, USA
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002100341	A2	20021219	WO 2002-US18388	20020612

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2001-297282PP 20010612

US 2003149107 A1 20030807 US 2002-167839 20020612

US 2001-297282PP 20010612

OS MARPAT 138:24543

GI



$A(CH_2)_p(NR^5)_q(CH_2)_nO$ — $(CH_2)_mCOXCOQ$ I

AB Biol. active title compds. [I; n = 1, 2; m, q, p = 0, 1; R5 = alkyl; R9 = H, halo, alkoxy; A = (halo-, alkyl-, perfluoromethyl-, alkoxy-, perfluoromethoxy-substituted) Ph, (Me-, Et-substituted) cycloalkyl, 5-6 membered heteroarom. ring having 1-2 N, S, O atoms; X = CH2, Q = OR1, R1 = Et; or X = CH2CR12R13, CH2CH(NHAc), Q = OR1, R1 = H, alkyl; or X = CH2CH2, Q = NR10R11; R12, R13 = H, Me; 1 of R10, R11 = H, alkyl, OH, the other = H, alkyl], were prepared Thus, 4-(2-fluorobenzyloxy)acetophenone (preparation given) in THF and DMPU was treated with a solution of Li bis(trimethylsilyl)amide at -60°; after 10 min, tert-Bu bromoacetate was added followed by stirring for an addnl. 10 min and warming to room temperature for 4 h to give tert-Bu 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyrate. The latter was stirred with CF3CO2H in CH2Cl2 to give 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyric acid. Tested I showed antidiabetic activity in a variety of tests. I are useful in treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:123000 CAPLUS

DN **136:183709**

TI Novel 1,4-dihydropyridines as bradykinin antagonists

IN Ikeda, Takafumi; Kato, Tomoki; Katsu, Yasuhiro; Kawai, Makoto; Kawamura, Mitsuhiro; Shishido, Yuji; Murase, Noriaki

PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.

SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002012235	A1	20020214	WO 2001-IB1346	20010726

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2000-224558PP	20000810
US 2002161006	A1	20021031	US 2001-903157	20010711
US 6653313	B2	20031125		
			US 2000-224558PP	20000810
AU 2001070947	A5	20020218	AU 2001-70947	20010726
			US 2000-224558PP	20000810
			WO 2001-IB1346 W	20010726
EP 1307449	A1	20030507	EP 2001-949836	20010726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-224558PP	20000810
			WO 2001-IB1346 W	20010726
BR 2001013071	A	20030701	BR 2001-13071	20010726
			US 2000-224558PP	20000810
			WO 2001-IB1346 W	20010726
JP 2004505973	T2	20040226	JP 2002-518210	20010726
			US 2000-224558PP	20000810
			WO 2001-IB1346 W	20010726

OS MARPAT 136:183709
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [wherein each A is independently halo; X = -(CH2)m-, -C(O)- or S(O)-; R1 and R2 are independently C1-4 alkyl; R3 is substituted azacycloalkyl etc.; R4 = ortho substituted Ph with substituents selected from substituted C1-7 alkyl, substituted C1-7 alkyl, substituted C1-7 alkoxy, amine, etc; R5 = hydrogen or C1-4 alkyl; m = 0, 1 or 2; and n = 0, 1, 2, 3, 4 or 5] are prepared and disclosed as bradykinin antagonists. Thus, II was prepared in seven steps via a modified Hantzsch synthesis involving the cyclocondensation of an intermediate benzylidene with an enamine to create the 1,4-dihydropyridine structural unit. The biol. activity of I was determined by their ability to inhibit the binding of bradykinin at its receptor sites in recombinant human bradykinin B2 receptor expressing CHO-K1 cells (IC50 values for prepared compds. ranged from 0.1 nM to 21 nM). The present invention also relates to pharmaceutical compns. containing such compds. and to the use of such compds. in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:851139 CAPLUS
DN **136:5997**
TI Biologically active 4H-benzo[1,4]oxazin-3-ones useful as PPARγ agonists or antagonists
IN Burris, Thomas P.; Combs, Donald W.; Rybczynski, Philip J.
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087862	A2	20011122	WO 2001-US15383	20010511
	WO 2001087862	A3	20020530		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-203860PP	20000512
				US 2001-854302 A	20010511
	US 2002165228	A1	20021107	US 2001-854302	20010511
	US 6555536	B2	20030429		
				US 2000-203860PP	20000512
	EP 1280784	A2	20030205	EP 2001-937335	20010511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-203860PP	20000512
				US 2001-854302 A	20010511
				WO 2001-US15383W	20010511

PATENT FAMILY INFORMATION:
FAN 2003:334658

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003083329	A1	20030501	US 2001-990461	20011121
				US 2000-203860PP	20000512
				US 2001-854302 A220010511	
	US 2002165228	A1	20021107	US 2001-854302	20010511
	US 6555536	B2	20030429		
				US 2000-203860PP	20000512
	EP 1314729	A1	20030528	EP 2002-258024	20021121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				US 2001-990461 A	20011121

OS MARPAT 136:5997
GI



I



II

AB The invention is directed to 4H-benzo[1,4]oxazin-3-ones I and their stereoisomers, esters, salts, and prodrugs, useful as peroxisome proliferator activated receptor gamma (PPARγ) agonists or antagonists [wherein: A = (un)substituted aryl, heterocyclyl, or alkyl; Z1 = H, alkyl, aryl, heterocyclyl, OH or derivs., CO2H or derivs., NH2 or derivs., halo, etc.; Z2 = H, halo, alkyl; or Z1Z2 = atoms to form fused aromatic ring; n = 0-3; G = CO2R1, COCO2R1, CONR1R2, CF3, P(O)(OR1)(OR2), SH, tetrazolyl, certain heterocycles, etc.; E = H, alkyl, -CH2CH2OC6H4(CH2)nG; X = H2, O; R1, R2 = H, alkyl, aryl, heterocyclyl, aralkyl; or R1R2 = atoms to form 5- to 10-membered ring; with addnl. provisos]. Pharmaceutical compns. comprising the compds. and methods of treating conditions such as NIDDM and obesity are also disclosed. Over 130 specific compds. are listed, and 5 of the preferred compds. are claimed. For instance, the silyl-protected intermediate 2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2H-1,4-benzoxazin-3(4H)-one (preparation given) underwent a sequence of N-alkylation with Br(CH2)6F, desilylation, Mitsunobu reaction with Me (2-hydroxyphenyl)acetate, and alkaline saponification, to give the preferred compound II. In an agonist intrinsic activity assay for induction of aP2 mRNA production, II gave a 64.9-fold increase over control.

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:298104 CAPLUS
DN **128:321640**
TI Preparation of 3-benzylpyrazoles as herbicides, plant desiccants, and defoliants.
IN Zagar, Cyrill; Hamprecht, Gerhard; Menges, Markus; Menke, Olaf; Schaefer, Peter; Westphalen, Karl-Otto; Misslitz, Ulf; Walter, Helmut
PA BASF A.-G., Germany
SO Ger. Offen., 40 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19645313	A1	19980507	DE 1996-19645313	19961104
	WO 9820000	A2	19980514	WO 1997-EP6057	19971103
	WO 9820000	A3	19981029		

W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

				DE 1996-19645313A 19961104
AU 9870017	A1	19980529	AU 1998-70017	19971103
			DE 1996-19645313A	19961104
			WO 1997-EP6057 W	19971103
EP 937046	A2	19990825	EP 1997-948864	19971103
R: CH, DE, FR, GB, LI				
			DE 1996-19645313A	19961104
			WO 1997-EP6057 W	19971103
JP 2001503421	T2	20010313	JP 1998-521039	19971103
			DE 1996-19645313A	19961104
			WO 1997-EP6057 W	19971103
US 6451734	B1	20020917	US 1999-297529	19990503
			DE 1996-19645313A	19961104
			WO 1997-EP6057 W	19971103

OS MARPAT 128:321640
GI



I

AB Title compds. [I; R1 = alkyl, haloalkyl, alkylsulfonyl, haloalkylsulfonyl; R2 = alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl; R3 = H, cyano, NO2, halo, alkyl, haloalkyl; X1-X5 = bond, (substituted) CH2, CH2CH2, CH:CH, OCH2, SCH2; R4-R8 = H, NO2, cyano, halo, etc.], were prepared Thus, 3-(2,3-dichlorobenzyl)-5-difluoromethoxy-1-methyl-1H-pyrazole (preparation given) was stirred with SO2Cl2 in CCl4 to give 4-chloro-3-(2,3-dichlorobenzyl)-5-difluoromethoxy-1-methyl-1H-pyrazole. The latter at 0.125 kg/ha gave very good postemergent herbicidal activity.

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:509397 CAPLUS
DN **121:109397**
TI Preparation of ester derivatives of 4-azasteroids as steroid 5α-reductase inhibitors.
IN Witzel, Bruce E.; Rasmusson, Gary H.; Tolman, Richard L.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9323041	A1	19931125	WO 1993-US4771	19930519

```
        W:  AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO,
            NZ, PL, RO, RU, SD, SK, UA, US
        RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
            BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
                                          US 1992-886022 A219920520
    AU 9342525        A1   19931213       AU 1993-42525    19930519
    AU 668181         B2   19960426
                                          US 1992-886022 A 19920520
                                          WO 1993-US4771 A 19930519
    EP 649306         A1   19950426       EP 1993-911362   19930519
    EP 649306         B1   20010110
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
                                          US 1992-886022 A 19920520
                                          WO 1993-US4771 W 19930519
    JP 07508039       T2   19950907       JP 1993-503838   19930519
                                          US 1992-886022 A 19920520
                                          WO 1993-US4771 W 19930519
    AT 198601         E    20010115       AT 1993-911362   19930519
                                          US 1992-886022 A 19920520
                                          WO 1993-US4771 W 19930519
    US 5610162        A    19970311       US 1994-338573   19941117
                                          US 1992-886022 B219920520
                                          WO 1993-US4771 W 19930519

PATENT FAMILY INFORMATION:
FAN  1997:204394
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   US 5610162        A     19970311      US 1994-338573   19941117
                                           US 1992-886022 B219920520
                                           WO 1993-US4771 W 19930519
     WO 9323041        A1    19931125      WO 1993-US4771   19930519
        W:  AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO,
            NZ, PL, RO, RU, SD, SK, UA, US
        RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
            BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
                                          US 1992-886022 A219920520
OS   MARPAT 121:109397
GI
```



I

AB Title compds. [I; a, b = single bonds, R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, alkyl, aralkyl; R3 = H, Me, Et, OH, NH2, SMe; n = 0-10; X = O, S; R4 = (substituted) alkyl, aryl,

heterocyclyl, cycloalkyl, amino, OH, etc.] were prepared as inhibitors of 5α-reductase and isoenzymes thereof. The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp (no data). Thus, 20-hydroxy-4-methyl-5α-4-azapregnan-3-one, 11-ethylthioundecanoic acid, DMAP, and DCC were stirred in CH2Cl2 at room temperature to give 20-[11-(ethylthio)undecanoyloxy]-4-methyl-5α-4-azapregnan-3-one.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.58	336.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.16	-7.63

STN INTERNATIONAL LOGOFF AT 14:33:41 ON 25 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:36:24 ON 25 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:36:42 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAR 2004 HIGHEST RN 667234-34-6
DICTIONARY FILE UPDATES: 24 MAR 2004 HIGHEST RN 667234-34-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10684644.2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1

G2 N,NH,NH2

G3 OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,NH,NH2

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 14:37:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

<    7.5% PROCESSED  312283 ITERATIONS                          5 ANSWERS

<    8.8% PROCESSED  367557 ITERATIONS                          5 ANSWERS

<    9.6% PROCESSED  400000 ITERATIONS                          5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.42

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS      30

L2            5 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             156.26     156.47

FILE 'CAPLUS' ENTERED AT 14:38:15 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 25 Mar 2004 VOL 140 ISS 13
FILE LAST UPDATED: 24 Mar 2004 (20040324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 3 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:610450 CAPLUS
DN 139:164813
TI Preparation of imidazo[1,2-a]pyridine derivatives as antifungal agents
IN Takemura, Makoto; Takahashi, Hisashi; Kawakami, Katsuhiro; Takeshita, Hiroshi; Kimura, Youichi; Watanabe, Jun; Sugimoto, Yuichi; Kitamura, Akihiro; Nakajima, Ryohei; Kanai, Kazuo; Fujisawa, Tetsunori
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003064422	A1	20030807	WO 2003-JP912	20030130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2002-22767 A 20020131

OS MARPAT 139:164813
IT **577776-39-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo[1,2-a]pyridine derivs. as antifungal agents with specific or selective 1,6-β-glucan)
RN 577776-39-7 CAPLUS
CN Benzenebutanoic acid, β-oxo-4-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



GI



I

AB The title compds. (I), salts thereof, or solvates of either [wherein the ring A = (un)substituted benzene ring or 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; R1 = H, halo, each (un)protected NH2, HO, or SH, NO2, cyano, CHO, CO2H, each (un)substituted CONH2, NH2, C1-10 alkyl, C1-10 alkylamino, C1-10 alkoxy, C1-10 alkylthio, C2-6 acyl, C2-7 alkoxycarbonyl, C3-10 cycloalkyl, C3-10 cycloalkylamino, C3-10 cycloalkyloxy, C3-10 cycloalkylthio, C4-10 cycloalkenyl, C4-10 cycloalkenylamino, C4-10 cycloalkenyloxy, C4-10 cycloalkenylthio, C6-10 aryl, C6-10 arylamino, or C6-10 aryloxy, etc.; R2 = H, halo, (un)protected NH2 or OH, NO2, cyano, CO2H, each (un)substituted CONH2, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C1-20 alkylamino, C1-20 alkoxy, C2-18 acyl, C2-18 alkoxycarbonyl, C3-10 cycloalkyl, C5-10 cycloalkenyl, C3-10 cycloalkylamino, or C4-16 cycloalkylalkyl, etc.; R3 = H, halo, (un)protected NH2, OH, or SH, NO2, cyano, CHO, CO2H, each (un)substituted CONH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkylthio, C2-5 acyl, or C2-5 alkoxycarbonyl, etc.; R4 = H, halo, (un)protected NH2 or OH, NO2, cyano, CO2H, SO3H, each (un)substituted CONH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-5 acyl, C2-5 alkoxycarbonyl, C1-6 alkylcarbonyloxy, or C1-6 alkyloxysulfonyl, etc.] are prepared These compds. have a wide spectrum of antifungal activity by a novel mechanism, i.e., specific or selective 1,6-β-glucan synthesis inhibition. Thus, 1-chloro-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile, (3S)-dimethylaminopyrrolidine, Et3N, and DMF were heated at 80° for 14 h in a sealed vessel to give 61% 1-[(3S)-dimethylpyrrolidin-1-yl]-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile formate (II). II showed min. inhibitory concentration of <0.063, <0.063, and 0.5 μg/mL against Saccharomyces cerevisiae, Candida glabrata, and C. krusei, resp. Pharmaceutical formulations, e.g. a capsule containing 1-[2-(diethylamino)ethylamino]-2-ethyl-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile, were described.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:417725 CAPLUS

DN 139:6773
TI Preparation of 4-oxoquinoline derivatives as ileal bile acid transporter inhibitors
IN Kurata, Hitoshi; Hasegawa, Tohru; Ikeda, Takuya; Kono, Keita
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 523 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003043992	A1	20030530	WO 2002-JP12077	20021119

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2001-353064 A 20011119

JP 2003212853	A2	20030730	JP 2002-333314	20021118
			JP 2001-353064 A	20011119

OS MARPAT 139:6773
IT **535969-65-4P 535969-97-2P 535970-53-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-oxoquinoline derivs. as ileal bile acid transporter inhibitors)
RN 535969-65-4 CAPLUS
CN Benzenepropanoic acid, 2-methoxy-β-oxo-4-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 535969-97-2 CAPLUS
CN Benzenepropanoic acid, 2-methoxy-β-oxo-4-(phenylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 535970-53-7 CAPLUS
CN Benzenepropanoic acid, 2,6-dimethoxy-β-oxo-4-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



GI



I

AB The title compds., e.g. I [R1 is aryl or the like; R2 is lower alkyl or the like; R3 is ADEGn+ (X-)n (wherein A is oxygen or the like; D is C1-12 alkylene or the like; E is a single bond or the like; Gn+ is substituted ammonio or the like; X- is an anion; and n is an integer of 1 or 2); R4, R6 and R7 are each hydrogen or the like; R5 is hydrogen or the like; and Ar is aryl or the like], are prepared In an in vitro test, compds. of this invention at 30 μg/mL gave 83.1% to 100% ileal bile acid transporter inhibition. A formulation is given.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:389980 CAPLUS
DN 138:401612
TI Preparation of carbostyryl derivatives and their use as oxytocin antagonists and therapeutics for treatment of premature delivery, miscarriage, dysmenorrhea, and galactorrhea
IN Shiraiwa, Masafumi; Ota, Shuji; Takefuchi, Ken; Uchida, Hiroshi; Saegusa, Mamoru; Mitsubori, Tomohiro; Yoshizawa, Masayuki
PA Teikoku Hormone Mfg. Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 142 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003146972	A2	20030521	JP 2001-348850	20011114

JP 2001-348850 20011114

OS MARPAT 138:401612

IT **528831-08-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carbostyryl derivs. as oxytocin antagonists)

RN 528831-08-5 CAPLUS

CN Benzenepropanamide, N-(3-methoxyphenyl)-β-oxo-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)



GI



I

AB Title derivs. I [Q1 = bond, CH2, CH2CH2, vinyl, CHMe, etc.; A = lower alkyl, (un)substituted cycloalkyl (condensed with hydrocarbyl ring), (un)substituted aryl, (un)substituted heterocyclyl (condensed with hydrocarbyl ring); R1 = H, lower alkyl; R2, R3 = H, (un)substituted lower alkyl(oxy), aralkyloxy, piperidinyl, etc.; R2R3 may be linked to form lower alkylenedioxy; Q2 = bond, CH2, CH2CH2, etc.; B = CO2H, lower alkoxycarbonyl, (un)substituted 2-pyridinyl, (un)substituted Ph, (un)substituted cyclohexyl, etc.] or their salts are claimed. The derivs. are also useful for termination of delivery prior to Caesarean section. Thus, 4-(2,3-dimethoxyphenyl)-7-methoxy-2-oxoquinoline was treated with Me 4-bromomethylbenzoate to give 56% I (AQ1 = 2,3-dimethoxyphenyl, R1-R3 = H, Q2B = 4-CH2C6H4CO2Me), which inhibited binding of [3H]-oxytocin to its receptor with IC50 of 0.972 μmol/L.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.71	171.18
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.08	-2.08

STN INTERNATIONAL LOGOFF AT 14:38:37 ON 25 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS	23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:40:14 ON 25 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:40:38 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAR 2004 HIGHEST RN 667234-34-6
DICTIONARY FILE UPDATES: 24 MAR 2004 HIGHEST RN 667234-34-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10684644.3

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1

G2 N,NH,NH2

G3 OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,NH,NH2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 14:41:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 13.3% PROCESSED 400000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.12

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 13

L2 4 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 155.84 156.05

FILE 'MARPAT' ENTERED AT 14:41:51 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 12)(20040319/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6696581 24 FEB 2004
DE 10317487 19 FEB 2004
EP 1389746 18 FEB 2004
JP 2004059557 26 FEB 2004
WO 2004015164 19 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 14:41:57 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 37823 TO ITERATE

21.7% PROCESSED	8205 ITERATIONS	(1 INCOMPLETE)	2 ANSWERS
42.6% PROCESSED	16127 ITERATIONS	(2 INCOMPLETE)	3 ANSWERS
66.1% PROCESSED	25000 ITERATIONS	(3 INCOMPLETE)	4 ANSWERS
90.0% PROCESSED	34023 ITERATIONS	(3 INCOMPLETE)	5 ANSWERS
97.0% PROCESSED	36672 ITERATIONS	(3 INCOMPLETE)	5 ANSWERS
98.9% PROCESSED	37411 ITERATIONS	(3 INCOMPLETE)	5 ANSWERS
100.0% PROCESSED	37823 ITERATIONS	(3 INCOMPLETE)	5 ANSWERS

SEARCH TIME: 00.01.57

L3 5 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	110.68	266.73

FILE 'CAPLUS' ENTERED AT 14:44:19 ON 25 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Mar 2004 VOL 140 ISS 13
FILE LAST UPDATED: 24 Mar 2004 (20040324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L4 1 L2

=> s l3
L5 5 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:964135 CAPLUS
DN 138:24543
TI Preparation of benzyloxyphenyloxobutyrates and related compounds for the treatment of metabolic disorders
IN Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.
PA Wellstat Therapeutics Corporation, USA
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002100341	A2	20021219	WO 2002-US18388	20020612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-297282PP	20010612
US 2003149107	A1	20030807	US 2002-167839	20020612
			US 2001-297282PP	20010612

OS MARPAT 138:24543
IT **478162-67-3P 478162-77-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzyloxyphenyloxobutyrates and related compds. for treatment of metabolic disorders)
RN 478162-67-3 CAPLUS
CN Benzenebutanoic acid, 4-(cyclopropylmethoxy)-γ-oxo- (9CI) (CA INDEX NAME)



RN 478162-77-5 CAPLUS
CN Benzenebutanoic acid, 3-(cyclopropylmethoxy)-γ-oxo- (9CI) (CA INDEX NAME)



IT **478163-21-2P 478163-33-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzyloxyphenyloxobutyrates and related compds. for treatment of metabolic disorders)

RN 478163-21-2 CAPLUS
CN Benzenebutanoic acid, 4-(cyclopropylmethoxy)-γ-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 478163-33-6 CAPLUS
CN Benzenebutanoic acid, 3-(cyclopropylmethoxy)-γ-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI



AB Biol. active title compds. [I; n = 1, 2; m, q, p = 0, 1; R5 = alkyl; R9 = H, halo, alkoxy; A = (halo-, alkyl-, perfluoromethyl-, alkoxy-, perfluoromethoxy-substituted) Ph, (Me-, Et-substituted) cycloalkyl, 5-6 membered heteroarom. ring having 1-2 N, S, O atoms; X = CH2, Q = OR1, R1 = Et; or X = CH2CR12R13, CH2CH(NHAc), Q = OR1, R1 = H, alkyl; or X = CH2CH2, Q = NR10R11; R12, R13 = H, Me; 1 of R10, R11 = H, alkyl, OH, the other = H, alkyl], were prepared Thus, 4-(2-fluorobenzyloxy)acetophenone (preparation given) in THF and DMPU was treated with a solution of Li bis(trimethylsilyl)amide at -60°; after 10 min, tert-Bu

bromoacetate was added followed by stirring for an addnl. 10 min and warming to room temperature for 4 h to give tert-Bu 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyrate. The latter was stirred with CF3CO2H in CH2Cl2 to give 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyric acid. Tested I showed antidiabetic activity in a variety of tests. I are useful in treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

=> d his

(FILE 'HOME' ENTERED AT 14:40:14 ON 25 MAR 2004)

FILE 'REGISTRY' ENTERED AT 14:40:38 ON 25 MAR 2004
L1 STRUCTURE UPLOADED
L2 4 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 14:41:51 ON 25 MAR 2004
L3 5 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:44:19 ON 25 MAR 2004
L4 1 S L2
L5 5 S L3

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:964135 CAPLUS
DN **138:24543**
TI Preparation of benzyloxyphenyloxobutyrates and related compounds for the treatment of metabolic disorders
IN Sharma, Shalini; Von Borstel, Reid W.; Hodge, Kirvin L.
PA Wellstat Therapeutics Corporation, USA
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100341	A2	20021219	WO 2002-US18388	20020612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-297282PP	20010612
	US 2003149107	A1	20030807	US 2002-167839	20020612
				US 2001-297282PP	20010612

OS MARPAT 138:24543
GI



I

AB Biol. active title compds. [I; n = 1, 2; m, q, p = 0, 1; R5 = alkyl; R9 = H, halo, alkoxy; A = (halo-, alkyl-, perfluoromethyl-, alkoxy-, perfluoromethoxy-substituted) Ph, (Me-, Et-substituted) cycloalkyl, 5-6 membered heteroarom. ring having 1-2 N, S, O atoms; X = CH2, Q = OR1, R1 = Et; or X = CH2CR12R13, CH2CH(NHAc), Q = OR1, R1 = H, alkyl; or X = CH2CH2, Q = NR10R11; R12, R13 = H, Me; 1 of R10, R11 = H, alkyl, OH, the other = H, alkyl], were prepared Thus, 4-(2-fluorobenzyloxy)acetophenone (preparation given) in THF and DMPU was treated with a solution of Li bis(trimethylsilyl)amide at -60°; after 10 min, tert-Bu bromoacetate was added followed by stirring for an addnl. 10 min and warming to room temperature for 4 h to give tert-Bu 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyrate. The latter was stirred with CF3CO2H in CH2Cl2 to give 4-[4-(2-fluorobenzyloxy)phenyl]-4-oxobutyric acid. Tested I showed antidiabetic activity in a variety of tests. I are useful in treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:380538 CAPLUS
DN **134:366686**
TI Preparation of 4-benzyloxyphenylalkanoic acids and analogs as thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
IN Malm, Johan; Litten, Chris; Apelqvist, Theresa; Hedfors, Asa; Brandt, Peter; Edvinsson, Karin; Gordon, Sandra
PA Karo Bio AB, Swed.
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001036365	A2	20010525	WO 2000-EP11554	20001116
	WO 2001036365	A3	20021107		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 1999-27056 A 19991117

OS MARPAT 134:366686
GI



I



II

AB The title compds. (I) [wherein R1 = (un)substituted (hetero)aryl, (cyclo)alkyl, alkenyl, or alkynyl; R2 = H, alkyl, alkenyl, alkynyl, alkoxy, or bioisosteric equivalent; or R1 and R2 may for an (un)substituted cycloalkyl ring; X = O, S, S(O), SO2, Se, Te, NRc, or S-S; R3 and R4 = independently halo, (cyclo)alkyl, alkenyl, alkynyl, alkoxy, CF3, OCF3, OCF2H, SMe, SCF3, CO2H, or bioisosteric equivalent; n = 0-3; Y = CO, O, S, CHRb, or NRc; Rb = H, halo, CF3, alkyl, alkenyl, alkynyl, alkoxy, (CH2)0-4OH, or bioisosteric equivalent; Rc = H, alkyl, alkenyl, alkynyl, or bioisosteric equivalent] were prepared as thyroid receptor ligands, preferably antagonists, for treatment of cardiac arrhythmias, thyrotoxicosis, and subclin. hyperthyroidism. For example, 2-Bu bromide was added to 3,5-dibromo-4-hydroxybenzeneacetic acid using TEA in acetone to give II (89%). I exhibited binding affinities to the thyroid hormone receptor α (ThRa) in the range of 100 nM to 10,000 nM.

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:509397 CAPLUS
DN **121:109397**
TI Preparation of ester derivatives of 4-azasteroids as steroid 5α-reductase inhibitors.
IN Witzel, Bruce E.; Rasmusson, Gary H.; Tolman, Richard L.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323041	A1	19931125	WO 1993-US4771	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886022 A219920520	
	AU 9342525	A1	19931213	AU 1993-42525	19930519
	AU 668181	B2	19960426		
				US 1992-886022 A 19920520	

				WO 1993-US4771 A	19930519
EP 649306		A1	19950426	EP 1993-911362	19930519
EP 649306		B1	20010110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
				US 1992-886022 A	19920520
				WO 1993-US4771 W	19930519
JP 07508039		T2	19950907	JP 1993-503838	19930519
				US 1992-886022 A	19920520
				WO 1993-US4771 W	19930519
AT 198601		E	20010115	AT 1993-911362	19930519
				US 1992-886022 A	19920520
				WO 1993-US4771 W	19930519
US 5610162		A	19970311	US 1994-338573	19941117
				US 1992-886022 B2	19920520
				WO 1993-US4771 W	19930519

PATENT FAMILY INFORMATION:

FAN 1997:204394

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5610162	A	19970311	US 1994-338573	19941117
			US 1992-886022 B2	19920520
			WO 1993-US4771 W	19930519
WO 9323041	A1	19931125	WO 1993-US4771	19930519
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			US 1992-886022 A2	19920520

OS MARPAT 121:109397

GI



I

AB Title compds. [I; a, b = single bonds, R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, alkyl, aralkyl; R3 = H, Me, Et, OH, NH2, SMe; n = 0-10; X = O, S; R4 = (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, amino, OH, etc.] were prepared as inhibitors of 5α-reductase and isoenzymes thereof. The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp (no data). Thus, 20-hydroxy-4-methyl-5α-4-azapregnan-3-one, 11-ethylthioundecanoic acid, DMAP, and DCC were stirred in CH2Cl2 at room temperature to give 20-[11-(ethylthio)undecanoyloxy]-4-methyl-5α-4-azapregnan-3-one.

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:245602 CAPLUS
DN **120:245602**
TI Preparation of 17-ethers and thioethers of 4-aza-steroids as steroid reductase inhibitors
IN Witzel, Bruce E.; Tolman, Richard L.; Rasmusson, Gary H.; Bakshi, Raman K.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323040	A1	19931125	WO 1993-US4746	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886031 A219920520	
	AU 9342521	A1	19931213	AU 1993-42521	19930519
	AU 668180	B2	19960426		
				US 1992-886031 A 19920520	
				WO 1993-US4746 A 19930519	
	EP 641204	A1	19950308	EP 1993-911358	19930519
	EP 641204	B1	20000816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				US 1992-886031 A 19920520	
				WO 1993-US4746 W 19930519	
	JP 07508038	T2	19950907	JP 1993-503831	19930519
				US 1992-886031 A 19920520	
				WO 1993-US4746 W 19930519	
	AT 195530	E	20000915	AT 1993-911358	19930519
				US 1992-886031 A 19920520	
				WO 1993-US4746 W 19930519	
	ES 2148229	T3	20001016	ES 1993-911358	19930519
				US 1992-886031 A 19920520	
	US 5536727	A	19960716	US 1994-338572	19941117
				US 1992-886031 B219920520	
				WO 1993-US4746 W 19930519	

PATENT FAMILY INFORMATION:
FAN 1996:469929

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5536727	A	19960716	US 1994-338572	19941117
				US 1992-886031 B219920520	
				WO 1993-US4746 W 19930519	
	WO 9323040	A1	19931125	WO 1993-US4746	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886031 A219920520	

OS MARPAT 120:245602
GI



I

AB Title compds. [I; a, b both = single bonds, and R2 = H; or a = double bond, b = single bond, and R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, (aryl)alkyl; R3 = H, Me, Et, OH, NH2, SMe; R4 = (substituted) alkyl, aryl, heterocyclyl; Z = XR4, (CHR1)nXR4; X = O, S, SO, SO2], were prepared as inhibitors of steroid 5α-reductase enzymes 1 and 2 (no data). The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp. Thus, 17-hydroxymethyl-4-methyl-5α-4-azaandrostan-3-one and diphenyldiazomethane in CH2Cl2 were treated dropwise with BF3.Et2O to give 17-diphenylmethoxymethyl-4-methyl-5α-4-azaandrostan-3-one.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:13416 CAPLUS
DN **116:13416**
TI Pressure- and heat-sensitive recording materials with good sensitivity, storability and image stability
IN Sano, Masajiro; Takashima, Masanobu; Satomura, Masato
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03142277	A2	19910618	JP 1989-282319	19891030
				JP 1989-282319	19891030

OS MARPAT 116:13416
AB The title materials utilizes coloration by contact between electron-donating leuco dye Ar1R1CH:CR2:CH:CHR3CR4R5Ar2 (Ar1, Ar2 = amine residue-containing aryl or heterocyclic group; R1-4 = H, monovalent group; R5 = aryl group-containing alkoxy group; R1-4 may bond together forming 4- to 12-membered rings with or without containing heteroatom) and electron-accepting compound

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.94	297.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.16	-4.16

STN INTERNATIONAL LOGOFF AT 14:45:44 ON 25 MAR 2004